• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

VirTrial Acquires SnapMD and Bolsters Virtual Care Management Platform

Share:

December 16, 2019

VirTrial, a portfolio company of Kinderhook Industries, LLC, announced today the acquisition of SnapMD, an industry-leading provider of telemedicine tools and services that improve patient engagement. The acquisition bolsters VirTrial’s capabilities with access to SnapMD’s telemedicine platform and technical expertise. In addition, the relationship enables integration of additional features and capabilities into VirTrial’s Virtual Care Management (VCM) platform to further establish VirTrial as the dominant global decentralized clinical trial (DCT) solution in the market.

The acquisition supports VirTrial’s goal of making hybrid decentralized clinical trials seamless for sponsors, sites, and patients. The VirTrial platform works with any device (Apple, Android, tablet and/or computer) and can be used by any site. Continuing that focus on flexibility and ease of use, new enhancements available via SnapMD technology will improve functionality and further simplify user experience.

“Our acquisition of SnapMD enables us to better implement our vision of making clinical trials easier for everyone involved from sponsors to sites and patients. By offering a simplified, straight-forward user experience and the ability for sponsors to include multiple countries with extensive features, VirTrial continues to set the bar in decentralized clinical trial platforms,” said Mark Hanley, CEO of VirTrial.

SnapMD’s VCM solution is used by providers nationwide to engage patients via a secure, HIPAA-compliant, cloud-based software platform. The company will operate as a subsidiary of VirTrial and will continue to provide its market-leading telemedicine solution across the healthcare space.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“We are extremely thrilled to join the VirTrial team and drive the evolution of telemedicine platforms in the clinical research industry,” said David Skibinski, CEO of SnapMD. “This transaction will enable SnapMD to further its commitment to improve access to care, regardless of setting, through an industry-best telemedicine solution and unmatched breadth of services.”

Source: BusinessWire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • SetPoint Medical Raises $80M to Advance Platform for Autoimmune DiseasesSetPoint Medical Raises $80M to Advance Platform for Autoimmune Diseases
  • Discovery Life Sciences Acquires Reachbio Research LabsDiscovery Life Sciences Acquires Reachbio Research Labs
  • New AI model for screening gingivitis developed in Hong KongNew AI model for screening gingivitis developed in Hong Kong
  • DocGo Reports Increased Revenue, Raises 2023 Revenue Guidance and More Digital Health EarningsDocGo Reports Increased Revenue, Raises 2023 Revenue Guidance and More Digital Health Earnings
  • Gyroscope advances gene therapy platform, merges with OrbitGyroscope advances gene therapy platform, merges with Orbit
  • Teladoc Health Completes Acquisition of InTouch Health, Creating Single Virtual Care Delivery Leader from Hospital to HomeCombined Company Enables Providers to Build Comprehensive Telemedicine StrategiesTeladoc Health Completes Acquisition of InTouch Health, Creating Single Virtual Care Delivery Leader from Hospital to HomeCombined Company Enables Providers to Build Comprehensive Telemedicine Strategies
  • 3 Healthcare Cybersecurity Trends to Watch in 20203 Healthcare Cybersecurity Trends to Watch in 2020
  • HealthEquity confirms offer to buy WageWorks for $50.50 per share in cashHealthEquity confirms offer to buy WageWorks for $50.50 per share in cash

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications